Hospital heart team capacity constraints continued to limit Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) sales in the third quarter of 2024, company executives said Thursday on ...

On Wednesday, Edwards Lifesciences Corp (EW) stock saw a modest uptick, ending the day at $66.52 which represents a slight increase of $0.71 or 1.08% from the prior close of $65.81. The stock opened ...

Irvine-headquartered Edwards Lifesciences has successfully completed the sale of its Critical Care product group to BD ...

California-based Edwards reaffirmed its full-year sales growth guidance of 8% to 10%. The medical device maker anticipates fourth-quarter sales to be between $1.33 to $1.39 billion, lower than ...

If you’re on the fence about investing in GE HealthCare Technologies Inc. or Edwards Lifesciences Corporation because you’re not sure how they measure up, it’s important to compare them on a few ...

Cosgrove brings a unique perspective to the field of mitral valve repair with the development of the Cosgrove-Edwards annuloplasty system. It is for use in the mitral or tricuspid position ...

Edwards Lifesciences Corp., Orange County’s most valuable publicly traded medical device maker, reported third quarter sales that signaled its biggest unit might be returning to prior sales growth ...